Clinical Gastroenterology and Hepatology

Article	Citations
Editorial Board	531
Front Cover	417
Hepatic Artery Pseudoaneurysm After Whipple Procedure	302
Table of Contents	299
Blue Notes	287
Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population?	269
Blue Notes	240
FODMAPs in IBS: Revisiting Restriction	218
National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States	208
hEDS and the Nosology of Disorders of Gut Brain Interaction	201
Symptom-Based Testing and Eradication of Helicobacter pylori and Risk of Gastric Cancer	191
Assessment and Significance of Histologic Activity in Crohn’s Disease	191
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study	186
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease	180
Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury	176
Who Examines the Colon Matters More Than What Is Removed	165
Perianal Disease in Pediatric-onset Crohn’s Disease: Incidence, Disease Course, and Long-term Outcomes	160
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials	140
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States	140
Update in the Treatment of the Complications of Cirrhosis	138
Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial	128
Correction	127
Editorial Board	127
Barrett’s Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study	122
Associations Between Sexual Orientation and Disorders of Gut-brain Interaction in Sexual Minority Populations	119

Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease	118
Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population	118
Fecal Microbiota-based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C. difficile Infection	118
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels	117
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist	116
Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis	114
Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial	111
Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry	110
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis	109
Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study	109
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease	108
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission	108
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient in Clinical Practice: An Investigational Procedure—What Can We Tell Patients?	105
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease	104
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary	103
AI-Assisted Capsule Endoscopy for Detection of Ulcers and Erosions in Crohn’s Disease: A Multicenter Validation Study	102
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis	102
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis	101
Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort	99
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis	95
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review	94
Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants	91
Elsewhere in the AGA Journals	90
Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial	90
Reply	89
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling	86
Editorial Board	86
Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?	85
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights From the Japan Polyp Study	84
Gut Microbiome Modulation by Antibiotics in Adult Asthma: A Human Proof-of-Concept Intervention Trial	84
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum	83
Attribution of Colonoscopy Risk Does Not FIT!	83
Reply	83
Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia	82
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment	81
Australasian Insights and Perspectives on the Burden of Chronic Liver Disease	81
Reply	79
An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States	79
Natural History of Patients Lost to Follow-up After Esophageal Food Impaction	78
Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome	78
Blue Notes	78
Table of Contents	77
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study	77
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy	77
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?	76
Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study	75
The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy	74
Daily or Twice Daily Treatment With Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis	73
Front Cover	73
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions	72

Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study	72
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis	72
Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion	71
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA	71
Blue Notes	70
Table of Contents	70
Reply	69
Editorial Board	68
Front Cover	67
Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals	67
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor	66
Response to “Recent Advancements and Future Perspectives of Per Oral Endoscopic Myotomy”	66
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe Not as Rare as You Think	65
Reply	65
Extraintestinal Symptoms in Irritable Bowel Syndrome Are Associated With Stress Reactivity and the Gut Microbiome in a Sex-dependent Manner	65
Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes	65
Reply	64
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps	64
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better?	63
Gastroparesis and Chronic Pancreatitis: Are They Truly Related?	63
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban	63
Mental Health Diseases Are Associated With Active Hepatitis C and Partly Drive Hepatocellular Carcinoma Trends in Veterans	63
An Unusual Complication of Endoscopic Ultrasound-guided Transgastric Liver Biopsy	63
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges	63
Constrictive and Hypertrophic Strictures in Ileal Crohn’s Disease	62
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process	62
Diet and Microbiome-Directed Therapy 2.0 for IBD	62
Value of Ammonia Testing in Clinical Practice	61
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis	61
Direct Oral Anticoagulants in Budd-Chiari Syndrome: Need a Closer Look!	61
Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery	61
Close Observation of the Lateral Walls of the Oropharynx During Esophagogastroduodenoscopy	61
Reply	60
Von Willebrand Factor Level Indicate Response to β-Blockers in Cirrhosis: Need a Closer Look!	60
Information for Authors and Readers	59
Editorial Board	58
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials	58
Reply	58
Foaming at the Varix: Sclerotherapy of Esophageal Varices via Intrahepatic Portal Vein Access	57
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network	57
Reply	57
Transient Uterine Prolapse: A Rare Complication of Endoscopic Polypectomy	57
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey	57
Cover	57
Cover	56
Reply	56
Reply	56
The New Kids on the Block: Emerging Complementary Colonoscopy Quality Metrics	55
Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome	55
Editorial Board	55
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies	55
Correction	54
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular, and Outcome Study	54
Upadacitinib in Mothers With Inflammatory Bowel Disease: Placental Transfer and Breast Milk Excretion	53
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula	53
Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations	53
Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth with Methanogens	53
The Severity of Reduced Esophageal Distensibility Parallels Eosinophilic Esophagitis Disease Duration	52
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis	52
Risk of Advanced Colorectal Neoplasia at Follow-up Colonoscopy After Synchronous Adenoma and Clinically Significant Serrated Polyp	52
Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy	51
Primary Sclerosing Cholangitis–Associated Pouchitis: A Distinct Clinical Phenotype	51
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations	51
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea	51
Hurdles in ERCP Trials: Do We Need to Change the Diagnostic Criteria for Post-ERCP Pancreatitis?	50
Uptake of Colorectal Cancer Screening in 45 to 49 Year Olds: An Early-Inning View from the Endoscopy Suite	50
Colon Volume by Computed Tomography and Scintigraphic Colonic Transit in Constipated Patients With or Without Redundant Colon	50
Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus	50
Long-Term Outcomes After Endoscopic Submucosal Dissection for T1 Colorectal Cancer: A Multicenter Prospective Study	50
Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)	50
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease	49
Population-based Screening for Hereditary Colorectal Cancer Variants in Japan	49
Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease	49
Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease	49
The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review	48
Clinical Outcomes of Intraductal Papillary Mucinous Neoplasms With Dilatation of the Main Pancreatic Duct	48
Environmental Toxins in Breast Milk and Risk of Early Onset Colorectal Cancer	48
From Onboarding to Excellence: Creating Gastroenterology Advanced Practice Provider Fellowship Programs That Benefit Practices, Patient Access, and Specialty Growth	48
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19	47
Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology	47

Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	47
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma	47
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease	47
All-cause and Cause-specific Mortality in Achalasia: A Nationwide Matched Cohort Study	46
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis	46
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease	46
Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease	46
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion	45
Birth Cohort Colorectal Cancer (CRC): Implications for Research and Practice	45
Editorial Board	45
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update	45
Front Cover	45
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis	45
Reply	45
Editorial Board	45
Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial	44
Declines in Colorectal Cancer Incidence and Mortality Rates Slow Among Older Adults	44
AGA Clinical Practice Update on Endoscopic Lifting Agents: Commentary	44
Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood	44
Knowledge, Attitudes, and Environment Related to Gastroenterology and Hepatology Care for Sexual and Gender Minorities	44
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis	44
Lymphangioma in a Child Managed With Debulking Surgery	44
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease	44
Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era	43
Internal Hernia and Volvulus After Endoscopic Ultrasound-guided Gastrojejunostomy	43
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction–associated Steatotic Liver Disease in Clinical Practice	43
Symptom Classes in Decompensated Liver Disease	43
Interventional Radiological Management for Budd-Chiari Syndrome: A 10-Year Retrospective, Multicenter Survey on 997 Patients in China	43
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease	42
Elsewhere in the AGA Journals	42
Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics	42
Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions: An International Randomized Controlled Trial	42
Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug!	42
Approach to Dietary Restriction in Irritable Bowel Syndrome	42
Preparing the Next Generation of Gastroenterologists to Tackle Climate Change	42
Abdomino-anal Dyscoordination in Defecatory Disorders	42
Diffuse Large B-Cell Duodenal Lymphoma Presenting With Obstruction and Pneumatosis	42
Reply	41
Reply	41
Information for Authors and Readers	41
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities	41
Front Cover	41
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma With Varices Using Red Dichromatic Imaging	41
Blue Notes	41
Editorial Board	41
Reply	41
Reply	40
Blue Notes	40
Reply	40
Elsewhere in the AGA Journals	40
Adult-Onset Fontan Circuit Failure: A Rare Cause of Protein-Losing Enteropathy	40
Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise	40
Editorial Board	39
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024	39
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation	39
Stratifying Risks of Ileal Pouch Outcomes	39
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease	39
Prediction of Postoperative Recurrence in Crohn’s Disease: Where Do We Go From Here?	39
Reply	39
Table of Contents	39
Dietary Fiber is Associated With Decreased Risk of Gastroesophageal Reflux Symptoms	39
Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometry	38
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn’s Disease	38
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases	38
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis	38
Is Baseline Metabolic Dysfunction-associated Steatohepatitis Fibrosis the Key Determinant for Survival After Bariatric Surgery?	38
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis	38
Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C	38
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease	38
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease	38
Reply	38
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study	38
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study	38
Establishing an Endobariatric Practice: Steps, Challenges, and Considerations Within a Private Practice Model	38
Perceptions, Definitions, and Therapeutic Interventions for Occasional Constipation: A Rome Working Group Consensus Document	37
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects	37
Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance	37
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	37
Letter to the editor - response	37
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis	37
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study	37
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis	37
Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018	37
Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in MASLD	36
Unaddressed Limitations of Alanine Aminotransferase as a Screening Tool for Pediatric Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease	36
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat	36
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study	36
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease	36
Gastric Emptying, Colon Filling, and Multiregional Gut Transit Delays Are Prevalent on Glucagon-Like Peptide-1 Agonists	36
Population-Attributable Fractions of Nonalcoholic Fatty Liver Disease on All-Cause and Cause-Specific Mortality Risk: How Large is the Impact?	35
Reply	35
Elsewhere in the AGA Journals	35
Blue Notes	35
Reply	35
Editorial Board	35